Brief: Simcere Pharmaceutical Says NDA For Rademikibart Accepted By NMPA
30/04/2026 09:43
April 30 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: NDA FOR RADEMIKIBART ACCEPTED BY NMPA ON APRIL 29, 2026 Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660